Aravive — Versartis — Technical Presentation (September 2016)
14 slides from Aravive's technical presentation, Sep 2, 2016
Slide 1: Treatment Adherence with Weekly, Twice-Monthly and Monthly Dosing of Somavaratan (VRS-317)
Eric Humphriss1, F. Naureen Sheikh1, Morgan Seaman2, David Ng2, George Bright1 1Versartis, Inc., Menlo Park, CA; 2ResearchPoint Global, Inc., Austin, TX Treatment Adherence with Weekly, Twice-Monthly and Monthly Dosing of Somavaratan (VRS-317), a Long-Acting Growth Hormone Treatment for Children wit
Slide 2: Disclosures
Disclosures Eric Humphriss, MBA, and F. Naureen Sheikh, PhD, are employees of Versartis, Inc David Ng, PhD, and Morgan Seaman are employees of ResearchPoint Global, a CRO receiving funding from Versartis, Inc George Bright, MD, is a consultant to Versartis and holds equity interests in Versartis, In
Slide 3: Challenges With Adherence to Daily Growth Hormone Treatment
Challenges With Adherence to Daily Growth Hormone Treatment Children with growth hormone deficiency (GHD) are often treated for multiple years with daily injections of recombinant human growth hormone (rhGH) replacement therapy, currently the only treatment available in North America and Europe Trea
Slide 4: Noncompliance to Daily rhGH Associated With Suboptimal Response
Noncompliance to Daily rhGH Associated With Suboptimal Response HV-SDS (+SEM) Level of Compliance ≥3 ≤1 >1 to <3 Missed doses/week: In a national survey of GH compliance by children in New Zealand (N=177), overall rate of noncompliance (≥1 missed injection/week, based on returned GH vials) was 66%1
Slide 5: Poor Adherence to rhGH Therapy Results in Suboptimal Growth
Poor Adherence to rhGH Therapy Results in Suboptimal Growth Height Velocity SDS & IGF-I Levels Impacted by Lack of Adherence one of the primary causes of GH therapy failure is patient non-adherence to the prescribed drug therapy Longitudinal study with 158 children between 4-16 years with GHD or SGA
Slide 6: Clinical Need for Long-Acting Growth Hormone
Clinical Need for Long-Acting Growth Hormone “Long-acting growth hormone compounds may represent an advance over daily GH injections because of increased convenience and differing pharmacodynamic properties, providing the potential for improved adherence and outcomes.” Growth Hormone Research Societ
Slide 7: Somavaratan (VRS-317)
Somavaratan (VRS-317) Increased Time on Target XTEN1 Long Tail of Hydrophilic Amino Acids Reduce Kidney Filtration XTEN2 Short Tail of Hydrophilic Amino Acids Reduce Receptor Mediated Clearance rhGH Same Sequence as Approved Products In clinical development for treatment of children and adults with
Slide 8: Somavaratan: Clinical Experience
Somavaratan: Clinical Experience Phase 1 - Adults1 30- to 60-fold increase in elimination half-life and longer IGF-I responses, compared with daily rhGH (N=50) Dose-proportional increases in magnitude and duration of IGF-I responses for up to 1 month after a single dose No study drug related serious
Slide 9: Methods: Monitoring Treatment Adherence
Methods: Monitoring Treatment Adherence Dosing events were reported by the caregiver using a smartphone-compatible electronic patient-reported outcome diary (eDiary) Prior to at-home dosing (initiated at beginning of extension study), caregivers were trained on: Preparation of somavaratan Subcutaneo
Slide 10: VISTA Study Design
VISTA Study Design 1Moore et al. J Clin Endocrinol Metab. 2016;101(3):1091-1097. 5.0 mg/kg Monthly 3.5 mg/kg Twice-Monthly 6–12 Months 12–30 Months (ongoing) 0–6 Months Somavaratan Dose Interval Phase 2a (Repeat Dose) Long-Term Safety Study 2.5 mg/kg Twice-Monthly 1.15 mg/kg Weekly 5.0 mg/kg Monthly
Slide 11: Patient Demographics and Baseline Characteristics
Patient Demographics and Baseline Characteristics Subjects Enrolled in Extension Study (n=60) Baseline age, Mean (SD) 7.8 (2.4) Gender, n (%) Female 26 (43%) Male 34 (57%) Race, n (%) White 50 (83%) Asian 4 (7%) Black or African American 3 (5%) American Indian or Alaska native 1 (2%) Other 2 (3%) Ba
Slide 12: Results: Reported Treatment Adherence after 24 Months Somavaratan Exposure
Results: Reported Treatment Adherence after 30 Months Somavaratan Exposure Parameter Somavaratan Starting Regimen Somavaratan Phase 3 Regimen 5.0 mg/kg Monthly (n=22) 2.5 mg/kg Twice-Monthly (n=18) 1.15 mg/kg Weeklya (n=20) 3.5 mg/kg Twice-Monthly (n=58) Doses Completed/Expected 131/131 213/213 195/
Slide 13: Conclusions
Conclusions Use of an eDiary device/application simplifies parent tracking of timing for and recording of at-home dosing events in this clinical trial With at-home dosing and over 2200 doses administered at the Phase 3 dose, treatment adherence rate was 99.6% With nearly 100% reported adherence for
Slide 14: Acknowledgments
Acknowledgments Investigators & Study Coordinators Patients and their families ResearchPoint Global Bracket, Inc. (eDiary)